Tag Archives: TG Therapeutics

The CEO & President of TG Therapeutics (NASDAQ: TGTX) is Buying Shares

Today, the CEO & President of TG Therapeutics (TGTX – Research Report), Michael S. Weiss, bought shares of TGTX for $351.5K. See today’s analyst top recommended stocks >> The Company has a Price to Book ratio of 32.0979. Currently, TG

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), Checkpoint Therapeutics Inc (CKPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TG Therapeutics (TGTX – Research Report), Checkpoint Therapeutics Inc (CKPT – Research Report) and uniQure NV (QURE – Research Report) with bullish

TG Therapeutics (TGTX) Receives a Buy from Cantor Fitzgerald

In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $17. The company’s shares closed on Friday at $7.56. Young commented: “: We reiterate

H.C. Wainwright Maintains a Buy Rating on TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $20. The company’s shares opened today at $8.17. White said: “Our $20 price target

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX) and Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Rhythm Pharmaceuticals Inc (RYTM – Research Report) with bullish sentiments. TG Therapeutics (TGTX) TG Therapeutics

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Irhythm Technologies (NASDAQ: IRTC) and Cytokinetics Inc (NASDAQ: CYTK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX – Research Report), Irhythm Technologies (IRTC – Research Report) and Cytokinetics Inc (CYTK – Research Report). TG Therapeutics (TGTX) In